Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …

EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
被引用次数：34 相关文章

[引用][C] Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open …

EA Joura, A Ulied, C Vandermeulen… - …, 2021 - researchportal.helsinki.fi
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45
years of age compared to women 16–26 years of age: An open-label phase 3 study …

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …

EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - …, 2021 - researchportal.tuni.fi
Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …

[引用][C] Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open …

EA Joura, A Ulied, C Vandermeulen… - …, 2021 - produccioncientifica.ucm.es

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: an open-label …

EA Joura, A Ulied, C Vandermeulen… - Vaccine …, 2021 - repository.uantwerpen.be
Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16 & …

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label …

EA Joura, A Ulied, C Vandermeulen, I Seppä, HA JJ… - Vaccine, 2021 - europepmc.org
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16-26 …

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …

EA Joura, A Ulied, C Vandermeulen, M Rua Figueroa… - VACCINE, 2021 - iris.unisr.it
Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
[PDF] cuny.edu

[PDF][PDF] Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open …

EA Joura, A Ulied, C Vandermeulen… - …, 2021 - lingqiaochen.commons.gc.cuny.edu
abstract Background: Efficacy of the nine-valent human papillomavirus(9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …

[引用][C] Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label …

EA Joura, A Ulied, C Vandermeulen… - …, 2021 - tobias-lib.ub.uni-tuebingen.de
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45
years of age compared to women 16-26 years of age: An open-label phase 3 study …

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label …

EA Joura, A Ulied, C Vandermeulen… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16-26 …